Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer's Disease

被引:99
作者
Chen, Win Ning [1 ]
Yeong, Keng Yoon [1 ,2 ]
机构
[1] Monash Univ Malaysia, Sch Sci, Bandar Sunway 47500, Selangor, Malaysia
[2] Monash Univ Malaysia, Trop Med & Biol TMB Multidisciplinary Platform, Bandar Sunway 47500, Selangor, Malaysia
关键词
Muscarinic antagonist; acetylcholine; Alzheimer's disease; cognitive dysfunction; amyloid-beta plaque; scopolamine; EXTRACELLULAR ACETYLCHOLINE; HYOSCINE BUTYLBROMIDE; MEMORY IMPAIRMENT; INDUCED AMNESIA; RECEPTORS; BINDING; MICE; BUTYRYLCHOLINESTERASE; ABNORMALITIES; CONVERSION;
D O I
10.2174/1871527319666200214104331
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Scopolamine as a drug is often used to treat motion sickness. Derivatives of scopolamine have also found applications as antispasmodic drugs among others. In neuroscience-related research, it is often used to induce cognitive disorders in experimental models as it readily permeates the bloodbrain barrier. In the context of Alzheimer's disease, its effects include causing cholinergic dysfunction and increasing amyloid-beta deposition, both of which are hallmarks of the disease. Hence, the application of scopolamine in Alzheimer's disease research is proven pivotal but seldom discussed. In this review, the relationship between scopolamine and Alzheimer's disease will be delineated through an overall effect of scopolamine administration and its specific mechanisms of action, discussing mainly its influences on cholinergic function and amyloid cascade. The validity of scopolamine as a model of cognitive impairment or neurotoxin model will also be discussed in terms of advantages and limitations with future insights.
引用
收藏
页码:85 / 93
页数:9
相关论文
共 66 条
[1]
The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review [J].
Ahmad, Syed S. ;
Khan, Shahzad ;
Kamal, Mohammad A. ;
Wasi, Umam .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2019, 18 (09) :657-667
[2]
Structural conversion of neurotoxic amyloid-β1-42 oligomers to fibrils [J].
Ahmed, Mahiuddin ;
Davis, Judianne ;
Aucoin, Darryl ;
Sato, Takeshi ;
Ahuja, Shivani ;
Aimoto, Saburo ;
Elliott, James I. ;
Van Nostrand, William E. ;
Smith, Steven O. .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (05) :561-U56
[3]
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly [J].
Aizenstein, Howard Jay ;
Nebes, Robert D. ;
Saxton, Judith A. ;
Price, Julie C. ;
Mathis, Chester A. ;
Tsopelas, Nicholas D. ;
Ziolko, Scott K. ;
James, Jeffrey A. ;
Snitz, Beth E. ;
Houck, Patricia R. ;
Bi, Wenzhu ;
Cohen, Ann D. ;
Lopresti, Brian J. ;
DeKosky, Steven T. ;
Halligan, Edythe M. ;
Klunk, William E. .
ARCHIVES OF NEUROLOGY, 2008, 65 (11) :1509-1517
[4]
Bioavailability and Pharmaco-therapeutic Potential of Luteolin in Overcoming Alzheimer's Disease [J].
Ali, Fahad ;
Siddique, Yasir Hasan .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2019, 18 (05) :352-365
[5]
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects [J].
Alvarez-Jimenez, Ricardo ;
Groeneveld, Geert Jan ;
van Gerven, Joop M. A. ;
Goulooze, Sebastiaan C. ;
Baakman, Anne Catrien ;
Hay, Justin L. ;
Stevens, Jasper .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (04) :1011-1021
[6]
A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis [J].
Andrew, Robert J. ;
Kellett, Katherine A. B. ;
Thinakaran, Gopal ;
Hooper, Nigel M. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (37) :19235-19244
[7]
The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting [J].
Antor, Maria A. ;
Uribe, Alberto A. ;
Erminy-Falcon, Natali ;
Werner, Joseph G. ;
Candiotti, Keith A. ;
Pergolizzi, Joseph V. ;
Bergese, Sergio D. .
FRONTIERS IN PHARMACOLOGY, 2014, 5
[8]
Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired-associate memory task [J].
Atri, A ;
Sherman, S ;
Norman, KA ;
Kirchhoff, BA ;
Nicolas, MM ;
Greicius, MD ;
Cramer, SC ;
Breiter, HC ;
Hasselmo, ME ;
Stern, CE .
BEHAVIORAL NEUROSCIENCE, 2004, 118 (01) :223-236
[9]
Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer's disease [J].
Bajo, R. ;
Pusil, S. ;
Lopez, M. E. ;
Canuet, L. ;
Pereda, E. ;
Osipova, D. ;
Maestu, F. ;
Pekkonen, E. .
SCIENTIFIC REPORTS, 2015, 5
[10]
AN ANALYSIS OF LEARNING DEFICITS PRODUCED BY SCOPOLAMINE [J].
BERGER, BD ;
STEIN, L .
PSYCHOPHARMACOLOGIA, 1969, 14 (04) :271-&